64
Global Public Health Team, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets Simon Berry

ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Embed Size (px)

Citation preview

Page 1: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Global Public Health Team, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

Simon Berry

Page 2: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

ColaLife is a charity registered in the UKCharity number: 1142516

• Small, independent and catalytic• Focus on saving children’s lives• Looking for global impact through

• Innovation• Generating robust evidence• Sharing findings and learning• Influencing healthcare strategies

• No commercial interest

2009

2010

2011

2012

2013

1985What is ColaLife and who am I?

Page 3: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Our starting point

Global Public Health Team, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

What we did What we learnt

2 3

How we can support

5

1

Nuggets

4

Page 4: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Our starting point

Global Public Health Team, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

What we did What we learnt

How we can support

2 3

5

1

Nuggets

4

Page 5: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Coca-Cola gets to most places, life-saving medicines don’t

Page 6: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Under 5 mortality is unacceptably high…

Page 7: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

…when compared with more developed countries

Page 8: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Diarrhoea is the second biggest killer

Diarrhoea

Page 9: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Sep 2010 | Enrolled into the J&J Innovation Bootcamp

Kris Pintens

Michelle Akande

Johan Offermans

Jane Berry

Alexander Bielders Simon Berry

Page 10: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Some of the ColaLife funders

Isenberg Family Charitable Foundation

Page 11: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Awards | The Kit Yamoyo has won many global awards

Page 12: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Our starting point

Global Public Health Team, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

What we did What we learnt

How we can support

2 3

5

1

Nuggets

4

Page 13: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

impact Mothers in underserved rural communities increase use of ORS and Zinc in home treatment of diarrhoea

purposeTarget communities in two under-served rural districts have improved access to ORS and Zinc

outputsProfit-driven supply chains improve availability of ADKs (anti-diarrhoea kits) in targeted communities in two underserved rural districts

Mothers/care-givers demonstrate awareness of ADKs and the benefits of the contents (ORS, Zinc and Soap)

access = ADK in the hand of an aware mother/care-giver

Availability = ADK in stock in retail outlets at community level

Generating robust evidence - the COTZ results framework

Page 14: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Dec 2011

The trial timeline

Page 15: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Mimicking Coca-Cola – creating a product people WANT

What we learnt

Litre sachets are too big

Measuring water was an issue

Willingness to pay

Preferred branding

Page 16: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 17: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 18: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 19: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 20: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Kit Yamoyo

Page 21: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 22: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 23: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 24: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 25: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 26: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 27: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 28: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 29: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15
Page 30: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Kit Yamoyo• Attractive• Affordable• Packaging is also:

• A measuring device for the water

• A mixing device• A storage device (the

soap tray is a lid)• A cup• And can be re-used

Page 31: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Mimicking Coca-Cola – Community-based marketing

Page 32: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Our starting point

Global Public Health Team, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

What we did What we learnt

How we can support

2 3

5

1

Nuggets

4

Page 33: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

Page 34: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

Page 35: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

Page 36: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

Page 37: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

Page 38: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

Page 39: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.

Page 40: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.

2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.

Page 41: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.

2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.

93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.

Page 42: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.

2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.

93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.

Page 43: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Manufacture

Assembly

Distribution

WholesaleK3.10

RetailK3.70

CustomerK5.00

Value

Kit Yamoyos

Demand PULLED the Kit Yamoyo into rural communities

Page 44: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

What we learned (1)

1. Value chain• Affordable• Profitable for all• Perceived value• Delivers to expectations (use of standards)• Product design• Attractive• Aspirational

2. Sensible use of subsidy• Top-end subsidy (non-corruption of the value chain)• Use of vouchers

Page 45: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

What we learned (2)

3. Behavior change works better with a product4. Organisations already exist but may need:• Bringing together in new ways• Capacity building

5. Partnership and shared risk• Donor support for trials and start-up• Donor support for awareness raising and training• Private sector for sustainable production

6. Think about multi-channels to market• Are the private sector needs different from the public sector

needs?

Page 46: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

We continue to learn – use of tablets in the scale-up

Page 47: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

We continue to learn – use of tablets in the scale-up

Page 48: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Our starting point

Global Public Health Team, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

Nuggets

What we did What we learnt

How we can support

2 3

5

1

4

Page 49: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Network diagram – the trial

http://www.colalife.org/2013/11/05/the-cotz-network-diagram/

Page 50: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Network diagram – the scale-up

Page 51: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Network diagram – sustainability

Page 52: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Voucher system – scale-up version

Page 53: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Voucher system – mark 2

Page 54: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Voucher system – scale-up version

Page 55: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Voucher system – scale-up version

Page 56: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Voucher system – scale-up version

Page 57: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Voucher system – scale-up version

Page 58: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Voucher system – scale-up version

Page 59: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Voucher system – scale-up version

Page 60: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Voucher system – scale-up version

Page 61: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Insights for Janssen? - A wider view of Access?

Access considerations might usefully be expanded:

1. Asking the customer• Review products destined for African market• Find out what people WANT not on what you think they NEED

2. Adapting better to the African context• Insights from working more closely with NGOs, local private sector

3. Advocacy with government, regulators, pharmacists4. Deliver Advantage

• All along the value chain – ‘price minus costing’ not ‘cost plus pricing’5. Awareness-raising

• Not just advertising• Invest in customer education, retailer or wholesaler training

6. Aspiration• Produce products that people aspire to use• The poor are as brand and quality aware as anybody else

Jane Berry
you could take this bullet off the slide if you can remember the examples
Page 62: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Our starting point

Global Public Health Team, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

What we did What we learnt

How we can support

2 3

5

1

Nuggets

4

Page 63: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Our partnership – possible next steps

1. It’s about partnership for global impact (not funding)

2. Sharing our learning to impact on the way Janssen does business in Africa (open access with support from ColaLife)

3. Use ColaLife as a catalyst for change• The grain in the oyster / the yeast in the bread

4. For this to work ColaLife would need a point of contact with the Management Board and Global Public Health team

Page 64: ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15

Questions?Comments?